Cargando…

A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children

Recently a framework was presented to assess whether pediatric covariate models for clearance can be extrapolated between drugs sharing elimination pathways, based on extraction ratio, protein binding, and other drug properties. Here we evaluate when a pediatric covariate function for midazolam clea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brussee, Janneke M., Krekels, Elke H. J., Calvier, Elisa A. M., Palić, Semra, Rostami-Hodjegan, Amin, Danhof, Meindert, Barrett, Jeffrey S., de Wildt, Saskia N., Knibbe, Catherijne A. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597607/ https://www.ncbi.nlm.nih.gov/pubmed/31250333 http://dx.doi.org/10.1208/s12248-019-0351-9

Ejemplares similares

Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach
por: Brussee, Janneke M., et al.
Publicado: (2018)

First‐Pass CYP3A‐Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates
por: Brussee, Janneke M., et al.
Publicado: (2018)

Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?
por: Calvier, Elisa A. M., et al.
Publicado: (2016)

Predicting CYP3A‐mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure
por: Brussee, Janneke M., et al.
Publicado: (2017)

Scaling Drug Clearance from Adults to the Young Children for Drugs Undergoing Hepatic Metabolism: A Simulation Study to Search for the Simplest Scaling Method
por: Calvier, E. A. M., et al.
Publicado: (2019)

Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory
por: Calvier, Elisa A. M., et al.
Publicado: (2018)

Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1‐OH‐midazolam in morbidly obese and weight loss surgery patients
por: Brill, MJE, et al.
Publicado: (2015)

The Influence of Drug Properties and Ontogeny of Transporters on Pediatric Renal Clearance through Glomerular Filtration and Active Secretion: a Simulation-Based Study
por: Cristea, Sînziana, et al.
Publicado: (2020)

Vancomycin Clearance in Obese Adults is not Predictive of Clearance in Obese Adolescents
por: Zhang, Tan, et al.
Publicado: (2023)

The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery
por: Brill, Margreke J., et al.
Publicado: (2015)

A Bodyweight-Dependent Allometric Exponent for Scaling Clearance Across the Human Life-Span
por: Wang, Chenguang, et al.
Publicado: (2012)

Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments
por: Calvier, Elisa A. M., et al.
Publicado: (2018)

The Influence of Normalization Weight in Population Pharmacokinetic Covariate Models
por: Goulooze, Sebastiaan C., et al.
Publicado: (2018)

The Predictive Value of Glomerular Filtration Rate-Based Scaling of Pediatric Clearance and Doses for Drugs Eliminated by Glomerular Filtration with Varying Protein-Binding Properties
por: Cristea, Sinziana, et al.
Publicado: (2020)

Midazolam Infusion and Disease Severity Affect the Level of Sedation in Children: A Parametric Time-to-Event Analysis
por: Upadhyay, Parth J., et al.
Publicado: (2021)

From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part II—Sensitivity to Physiological and Physicochemical Properties
por: Krekels, E H J, et al.
Publicado: (2012)

Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants
por: Krekels, Elke H. J., et al.
Publicado: (2015)

Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults
por: van Rongen, Anne, et al.
Publicado: (2017)

Systematic Evaluation of the Descriptive and Predictive Performance of Paediatric Morphine Population Models
por: Krekels, Elke H. J., et al.
Publicado: (2010)

The role of population PK–PD modelling in paediatric clinical research
por: De Cock, Roosmarijn F. W., et al.
Publicado: (2010)

A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction
por: Ke, A B, et al.
Publicado: (2012)

Genetic Variation in CYP3A43 Explains Racial Difference in Olanzapine Clearance
por: Bigos, Kristin L., et al.
Publicado: (2011)

Children Are Not Small Adults, but Can We Treat Them As Such?
por: Krekels, Elke H.J., et al.
Publicado: (2019)

CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults
por: Muhareb, Amin, et al.
Publicado: (2023)

Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5
por: Yoshida, K, et al.
Publicado: (2016)

Dose‐linearity of the pharmacokinetics of an intravenous [(14)C]midazolam microdose in children
por: van Groen, Bianca D., et al.
Publicado: (2019)

Inter-individual variation in midazolam clearance in children
por: Altamimi, Mohammed I, et al.
Publicado: (2015)

Inhibition of CYP3A-mediated Midazolam Metabolism by Kaempferia Parviflora
por: Kashiwabuchi, Yumika, et al.
Publicado: (2022)

Cold-Induced Lipoprotein Clearance in Cyp7b1-Deficient Mice
por: Evangelakos, Ioannis, et al.
Publicado: (2022)

From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part I–Extrapolation of a Covariate Model From Morphine to Zidovudine
por: Krekels, E H J, et al.
Publicado: (2012)

Unravelling the pharmacokinetics of aflatoxin B1: In vitro determination of Michaelis–Menten constants, intrinsic clearance and the metabolic contribution of CYP1A2 and CYP3A4 in pooled human liver microsomes
por: Lootens, Orphélie, et al.
Publicado: (2022)

Evidence of CYP3A Allosterism In Vivo: Analysis of Fluconazole and Midazolam Interaction
por: Yang, Jing, et al.
Publicado: (2011)

CYP1A2 polymorphism and theophylline clearance in Korean non-smoking asthmatics
por: Yim, Eun-Young, et al.
Publicado: (2013)

Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity
por: Wiebe, Sabrina T., et al.
Publicado: (2020)

The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study
por: van Groen, Bianca D., et al.
Publicado: (2020)

Intraindividual Variability in Absolute Bioavailability and Clearance of Midazolam in Healthy Individuals
por: Kvitne, Kine Eide, et al.
Publicado: (2023)

Vitamin D3 Is Transformed into 1,25(OH)(2)D(3) by Triggering CYP3A11(CYP3A4) Activity and Hydrolyzing Midazolam
por: Zhu, Hanfei, et al.
Publicado: (2019)

Pregnancy related hormones increase CYP3A mediated buprenorphine metabolism in human hepatocytes: a comparison to CYP3A substrates nifedipine and midazolam
por: Fashe, Muluneh M., et al.
Publicado: (2023)

Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance
por: Scotcher, Daniel, et al.
Publicado: (2016)

Midazolam as a Probe for Heterotropic Drug-Drug Interactions Mediated by CYP3A4
por: Denisov, Ilia G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_30offlnrk8of8e6deik91h2qd2